Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
O. Germershaus, T. Lühmann, J.-C. Rybak, J. Ritzer & L. Meinel. (2015) Application of natural and semi-synthetic polymers for the delivery of sensitive drugs. International Materials Reviews 60:2, pages 101-131.
Read now
Read now
Daniel A. Nadeau. (2013) Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach. Postgraduate Medicine 125:3, pages 112-126.
Read now
Read now
Gregory E Peterson. (2009) Analog insulin detemir for patients with type 1 and type 2 diabetes: a review. Diabetes, Metabolic Syndrome and Obesity 2, pages 31-36.
Read now
Read now
Rattan Juneja. (2008) Hyperglycemia Management in the Hospital: About Glucose Targets and Process Improvements. Postgraduate Medicine 120:4, pages 38-50.
Read now
Read now
Oliver Schöffski, Lusine Breitscheidel, Ursula Benter, Franz-Werner Dippel, Markus Müller, Michael Volk & Martin Pfohl. (2008) Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. Journal of Medical Economics 11:4, pages 695-712.
Read now
Read now
Articles from other publishers (51)
Anubhav Pratap-Singh, Yigong Guo, Alberto Baldelli & Anika Singh. (2023) Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs. Pharmaceutics 15:9, pages 2265.
Crossref
Crossref
NIKHAR VISHWAKARMA & SURESH P. VYAS. (2023) FORMULATION AND IN VITRO CHARACTERISATION OF GLUCOSE-RESPONSIVE NANOCAPSULES FOR THE DELIVERY OF M-INSULIN. International Journal of Applied Pharmaceutics, pages 178-185.
Crossref
Crossref
Jugal Kishor Sharma, Dinesh Sharma & Amit Gupta. (2022) A glorious past, dynamic present and a promising future: Insulin at 100. Journal of the Royal College of Physicians of Edinburgh 52:1, pages 59-64.
Crossref
Crossref
Esteban Cruz & Veysel Kayser. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
47
69
.
Jiangjie Lu, Yong Zeng, Xiulin Yi, Hongmei Zhang, Lin Zhu, Lixin Jiang, Jing Li, Wei Zhou, Hong Zhu & Aijun Xiong. (2020) Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection. BMC Complementary Medicine and Therapies 20:1.
Crossref
Crossref
Thomas Semlitsch, Jennifer Engler, Andrea Siebenhofer, Klaus Jeitler, Andrea Berghold & Karl Horvath. (2020) (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020:11.
Crossref
Crossref
Stefano Del Prato. (2020) How conclusive is the CONCLUDE trial?. Diabetologia 63:4, pages 692-697.
Crossref
Crossref
Lisa R. Volpatti, Morgan A. Matranga, Abel B. Cortinas, Derfogail Delcassian, Kevin B. Daniel, Robert Langer & Daniel G. Anderson. (2019) Glucose-Responsive Nanoparticles for Rapid and Extended Self-Regulated Insulin Delivery. ACS Nano 14:1, pages 488-497.
Crossref
Crossref
Elisabetta Muntoni, Elisabetta Marini, Nahid Ahmadi, Paola Milla, Corrado Ghè, Alessandro Bargoni, Maria Teresa Capucchio, Elena Biasibetti & Luigi Battaglia. (2019) Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies. Acta Diabetologica 56:12, pages 1283-1292.
Crossref
Crossref
A. K. J. Gradel, T. Porsgaard, J. Lykkesfeldt, T. Seested, S. Gram-Nielsen, N. R. Kristensen & H. H. F. Refsgaard. (2018) Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. Journal of Diabetes Research 2018, pages 1-17.
Crossref
Crossref
Huang-Tz Ou, Tsung-Ying Lee, Ye-Fong Du & Chung-Yi Li. (2018) Comparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999-2013 in Taiwan. British Journal of Clinical Pharmacology 84:2, pages 379-391.
Crossref
Crossref
Barbara Bohn, Artur Zimmermann, Christian Wagner, Sigrun Merger, Desirée Dunstheimer, Florian Kopp, Katja Gollisch, Volker Zindel & Reinhard W. Holl. (2017) Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry. Diabetes Research and Clinical Practice 129, pages 52-58.
Crossref
Crossref
M. C. Gerards, J. S. de Maar, T. G. Steenbruggen, J. B. L. Hoekstra, T. M. Vriesendorp & V. E. A. Gerdes. (2016) Add-on treatment with intermediate-acting insulin versus sliding-scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy: a randomized crossover study. Diabetes, Obesity and Metabolism 18:10, pages 1041-1044.
Crossref
Crossref
Zheng Ling, Jiao Qi-Qing, Wang Yu, Bian Fei, Qu Shu-Jie, Wan Shu-Bo, Peng Zhen-Ying & Bi Yu-Ping. (2016) Transgenic Expression and Identification of Recombinant Human Proinsulin in Peanut. Brazilian Archives of Biology and Technology 59:0.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
111
144
.
D. Russell-Jones, M.-A. Gall, M. Niemeyer, M. Diamant & S. Del Prato. (2015) Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 25:10, pages 898-905.
Crossref
Crossref
Lori Berard, Brett Cameron, Vincent Woo & John Stewart. (2015) Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction. Canadian Journal of Diabetes 39:4, pages 296-301.
Crossref
Crossref
S. Franzè, F. Cilurzo & P. Minghetti. (2015) Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy. BioDrugs 29:2, pages 113-121.
Crossref
Crossref
Christopher Sorli. (2014) New Developments in Insulin Therapy for Type 2 Diabetes. The American Journal of Medicine 127:10, pages S39-S48.
Crossref
Crossref
Jen-Chieh Lin, Wen-Yi Shau & Mei-Shu Lai. (2014) Long-acting Insulin Analogues and Diabetic Retinopathy: A Retrospective Cohort Study. Clinical Therapeutics 36:9, pages 1255-1268.
Crossref
Crossref
Michelle R. Joshi, Nianhuan Yao, Kenneth A. Myers & Zhiyu Li. (2013) Human Serum Albumin and p53-Activating Peptide Fusion Protein Is Able to Promote Apoptosis and Deliver Fatty Acid-Modified Molecules. PLoS ONE 8:11, pages e80926.
Crossref
Crossref
Gillian M. Keating. (2013) Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus. Drugs & Therapy Perspectives 29:10, pages 297-302.
Crossref
Crossref
Gillian M. Keating. (2013) Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus. Drugs 73:6, pages 575-593.
Crossref
Crossref
G. Grunberger. (2013) The need for better insulin therapy. Diabetes, Obesity and Metabolism 15:s1, pages 1-5.
Crossref
Crossref
S. Korsatko, K. Glettler, K. J. Olsen, A. Wutte, G. Bock, G. Koehler, J. K. Mader, B. Semlitsch & T. R. Pieber. (2012) A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Diabetes, Obesity and Metabolism 15:3, pages 241-245.
Crossref
Crossref
Gillian M. Keating. (2012) Insulin Detemir. Drugs 72:17, pages 2255-2287.
Crossref
Crossref
E. Delgado. (2012) Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. International Journal of Clinical Practice 66:3, pages 281-288.
Crossref
Crossref
Carla A. Borgoño & Bernard Zinman. (2012) Insulins: Past, Present, and Future. Endocrinology and Metabolism Clinics of North America 41:1, pages 1-24.
Crossref
Crossref
Ilias N. Migdalis. (2011) Insulin analogs versus human insulin in type 2 diabetes. Diabetes Research and Clinical Practice 93, pages S102-S104.
Crossref
Crossref
Yan-Qi Chu, Li-Jian Cai, De-Chun Jiang, Dan Jia, Su-Ying Yan & Yu-Qin Wang. (2010) Allergic shock and death associated with protamine administration in a diabetic patient. Clinical Therapeutics 32:10, pages 1729-1732.
Crossref
Crossref
. (2010) Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine 362:10, pages 959-960.
Crossref
Crossref
Mingshi Yang & Sven Frokjaer. 2009. Delivery Technologies for Biopharmaceuticals. Delivery Technologies for Biopharmaceuticals
9
28
.
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J.-P. Hallé, I. Hramiak, P. Johnston & M. Davis. (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 52:9, pages 1778-1788.
Crossref
Crossref
Hyoseok Kang, Kyu J Ahn, Ju Y Choi, Hye J Park, So J Park & Su K Lee. (2009) Efficacy of insulin glargine in perioperative glucose control in type 2 diabetic patients. European Journal of Anaesthesiology 26:8, pages 666-670.
Crossref
Crossref
Juhaeri Juhaeri, Shujun Gao & Wanju S. Dai. (2009) Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiology and Drug Safety 18:6, pages 497-503.
Crossref
Crossref
M. Monami, N. Marchionni & E. Mannucci. (2009) Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, Obesity and Metabolism 11:4, pages 372-378.
Crossref
Crossref
M. Yenigun & M. Honka. (2009) Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study. International Journal of Clinical Practice 63:3, pages 425-432.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
R.C.L. Page. 2009.
689
702
.
Matteo Monami, Niccolò Marchionni & Edoardo Mannucci. (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Research and Clinical Practice 81:2, pages 184-189.
Crossref
Crossref
Jenny M. Meegan, Inga F. Sidor, Jörg M. Steiner, Delphine Sarran & J. Lawrence Dunn. (2008) Chronic pancreatitis with secondary diabetes mellitus treated by use of insulin in an adult California sea lion. Journal of the American Veterinary Medical Association 232:11, pages 1707-1712.
Crossref
Crossref
Lynne R Ferrari. (2008) New insulin analogues and insulin delivery devices for the perioperative management of diabetic patients. Current Opinion in Anaesthesiology 21:3, pages 401-405.
Crossref
Crossref
R I G Holt & P H Sönksen. (2008) Growth hormone, IGF-I and insulin and their abuse in sport. British Journal of Pharmacology 154:3, pages 542-556.
Crossref
Crossref
Arturo Rolla. (2008) Pharmacokinetic and Pharmacodynamic Advantages of Insulin Analogues and Premixed Insulin Analogues Over Human Insulins: Impact on Efficacy and Safety. The American Journal of Medicine 121:6, pages S9-S19.
Crossref
Crossref
Morali D. Sharma, Alan J. Garber & John A. Farmer. (2008) Role of Insulin Signaling in Maintaining Energy Homeostasis. Endocrine Practice 14:3, pages 373-380.
Crossref
Crossref
Harvey Chiu & Catherine Pihoker. 2008. Epidemiology of Pediatric and Adolescent Diabetes. Epidemiology of Pediatric and Adolescent Diabetes
303
322
.
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Crossref
T. Heise & T. R. Pieber. (2007) Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity and Metabolism 9:5, pages 648-659.
Crossref
Crossref
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas & Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, pages 421-433.
Crossref
Crossref
Erkan Hassan. (2007) Hyperglycemia management in the hospital setting. American Journal of Health-System Pharmacy 64:10_Supplement_6, pages S9-S14.
Crossref
Crossref
W T Cefalu, S Waldman & S Ryder. (2007) Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents. Clinical Pharmacology & Therapeutics 81:5, pages 636-649.
Crossref
Crossref